Drugs / ORM-12741
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT03440021 | Mar → Dec 2018 | — | University of Cape Town | Completed | No outcome recorded |
| Phase 1 | NCT02303860 | Oct 2014 → Jan 2015 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02319057 | Sep 2014 → Feb 2015 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01068028 | Feb → Jun 2010 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT00817544 | Jan → Feb 2009 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT00829907 | Jan → Jun 2009 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT00818740 | Jan → Jun 2009 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT00792493 | Dec 2008 → Jun 2009 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT00693316 | Jul 2008 → Oct 2009 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT02471196 | Aug 2015 → Oct 2017 | Alzheimer disease | Orion Corporation, Orion Pharma | Completed | Missed primary |
| Phase 2 | NCT01324518 | Apr 2011 → Sep 2012 | Alzheimer disease | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT00831077 Comparator | Jan → Apr 2009 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2013-03-21 | Orion Corporation, Orion Pharma | Results Orion Corporation presented promising Phase II data for new Alzheimer's disease drug at AAN Annual Meeting orionpharma.com ↗
According to a Phase IIa study, presented yesterday at American Academy of Neurology's Annual Meeting in San Diego, ORM-12741 showed significant positive effects on episodic memory in patients with moderate Alzheimer's disease. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-03-21 | Orion Corporation, Orion Pharma | Orion Corporation presented promising Phase II data for new Alzheimer's disease drug at AAN Annual Meeting orionpharma.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORM-12741 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01324518 ↗ |
| Known as | DB-105 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297312 ↗ |
| Action | Inhibit | “Alpha-2c adrenergic receptor antagonist” CHEMBL4297312 ↗1“alpha-2C adrenoceptor (AR)-antagonist” NCT02471196 ↗ |
| Modality | Small molecule | — CHEMBL4297312 ↗ |
| Route | Intravenous | “i.v., oral solution and oral capsule forms.” NCT00818740 ↗ |
| Route | Oral | “i.v., oral solution and oral capsule forms.” NCT00818740 ↗ |
| Target | ADRA2C | “Alpha-2c adrenergic receptor antagonist” CHEMBL4297312 ↗ |